期刊文献+

高效液相色谱法测定罗格列酮钠片含量及有关物质 被引量:3

Determination of Content and Its Related Substances of Rosiglitazone Sodium Tablets by HPLC
下载PDF
导出
摘要 建立高效液相色谱法测定罗格列酮钠片含量及有关物质。该法采用ZorbaxSB-C18色谱柱(4.6mm×250mm,5μm),流动相为0.1mol/L乙酸钠溶液(用稀乙酸调节至pH5.5)-甲醇(30∶70),流速1mL·min-1,检测波长为245nm。在进样量(0.4~4.8)μg时,与峰面积呈良好线性,r=0.9999(n=7),平均回收率100.1%,日内和日间RSD分别为0.56%及0.63%(n=9)。有关物质可得到很好分离。该法简便、准确、专属。 To determine the content and its related substances of Rosiglitazone Sodium tablets by HPLC the Zorbax SB-C18 column (4.6 mm×250 mm, 5 μm)was used, 0.1 mol·L^-1 sodium acetate solution (adjusted to pH 5.5 with acetate): methanol (30:70) as the mobile phase, at a flow rate of 1 mL·min^-1, at detection wavelength 245 nm. The linearity of peak area was good when the injected quantity of Rosiglitazone sodium was in the range of (0.4-4.8) μg(r=0.999 9, n=7). The recovery of this method was 100.1%, the intra-day RSD and inter-day RSD were 0.56% and 0.63%(n=9) respectively. The related substance can be separated as well. It is conclused this method is convenient, accurate and specific.
出处 《科学技术与工程》 2006年第12期1678-1680,共3页 Science Technology and Engineering
关键词 罗格列酮钠片 高效液相色谱法 含量 有关物质 Rosiglitazone Sodium tablets HPLC content related substance
  • 相关文献

参考文献4

  • 1[1]Reaven G M.Banting lecture 1988.Role of insulin resistance in human disease.Diabetes,1988; 37 (12):1595
  • 2[2]Reiusser J,Auwerk J,Vidal H.Regulation of gene expression by activation of the peroxisome proliferator-activated receptor gamma with rosiglitazone (BRL 49563) in human adipocytes.Biochem Biophys Res Commun,1999; 265 (1):265
  • 3[3]Cantello B C,Cawthorone M A.The synthesis of BRL-49653-A novel and potent antihyperglycaemic agent.Bioorg Mad Chem Lett,1994;4(10):1181-1184
  • 4龚正华,黄世杰,张中启,袁莉,龚晓霞,沈伽弟,李玉凤,宫泽辉.罗格列酮钠在2种糖尿病动物模型上的降糖作用[J].中国新药杂志,2004,13(8):707-709. 被引量:6

二级参考文献7

  • 1[2]Tominaga M,Igarashi M,Daimon M,et al.Thiazolidindiones(AD-4833 and CS-045 improve hepatic insulin resistance in streptozotoin-induced diabetic rats[J].Endocrine J,1993,40(3):343-349.
  • 2[3]Katsumata K.Effect of a single administration of tolbutamide on the occurrence of alloxan diabetes[J].Horm Metabol Res,1990,22(3):192-193.
  • 3[4]Fujita T,Sugiyama Y,Taketomi S,et al.Reduction of insulin resistance in obese and or diabetic animals by 5-[4-(1-methycyclohexylmethoxy)-benzyl]- thiazolidine-2,4-dione(ADD-3878,U-63,287,Ciglitazone),a new antidiabetic agent[J].Diabetes,1983,32(9):804-810.
  • 4[5]Connor SC,Hughes MG,Moore G,et al.Antidiabetic efficacy of BRL 49653,a potent orally active insulin sensitizing agent,assessed in the C57L/KsJ db/db diabetic mouse by non-invasive 1H NMR studies of urine[J].J Pharm Pharmacol,1997,49(3):336-344.
  • 5[6]Barman Balfour JA,Plosker GL.Rosiglitazone[J].Drugs,1999 57(6):921-930.
  • 6[7]Oakes ND,Kennedy CJ,Jenkins AB,et al.A new antidiabetic agent,BRL 49653 reduces lipid availability and improves insulin action and glucoregulation in the rat[J].Diabetes,1994,43(10):1203-1210.
  • 7沈素.文迪雅[J].中国新药杂志,2001,10(5):382-383. 被引量:9

共引文献5

同被引文献16

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部